Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2020, Volume and Issue: 19(2), P. 2454 - 2454

Published: April 21, 2020

Heart failure with preserved ejection fraction (CHpEF) is a common but difficult to diagnose disease. CHpEF associated comorbidity, therefore, the symptoms are not always specific, which often leads long-term diagnostic process and inability treat underlying disease prevent its complications. The most affordable cost-effective imaging method for diagnosis transthoracic echocardiography. Diagnosis algorithms HFpEF were first systematized published in 2019, will improve patient management serious

Language: Английский

---

Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure

Kardiologiia, Journal Year: 2020, Volume and Issue: 60(4), P. 101 - 108

Published: May 4, 2020

Current biomarkers allow diagnosing a wide array of pathological processes and evaluating effects therapies prognosis for cardiological patients. This review focuses on possibility using N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor tumorigenicity 2 (sST2), galectin-3, other in patients with chronic heart failure the risk life-threatening ventricular tachyarrhythmias sudden cardiac death.

Language: Английский

---

Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I

Russian Journal of Cardiology, Journal Year: 2021, Volume and Issue: 26(4), P. 4368 - 4368

Published: May 22, 2021

Aim . To assess the healthcare system costs for management of patients with heart failure (HF) based on a retrospective analysis primary medical documentation. Material and methods We performed outpatient records 1000 patients, followed up 1 year by general practitioner or cardiologist in ambulatory clinic 7 Russian regions. The study included men women over 18 years age an established class II-IV HF at least one hospitalization due to acute decompensated within 12-month follow-up. Results final 888 (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). preserved ejection fraction (EF) was detected 47,86% mid-range — 40,54%, reduced 11,6%. Only 16% there improved more HF. Hypertension coronary artery disease were predominant etiology pattern Preserved EF often 60 HTN obesity, as well same group. There sufficient follow-up rate, but extent examinations do not correspond recommended one. prescription rate renin-angiotensin-aldosterone (RAAS) inhibitors corresponds one, is high frequency prescribing angiotensin II receptor blockers (ARBs). β-blockers loop diuretics (mainly torasemide) increased comparison previous studies, while thiazide decreased. In EF, sacubitril/valsartan only 14,7%, 83,3%, mineralocorticoid antagonists (MCRA) 72,5%. midrange sharp decrease RAAS inhibitors, β-blockers, MCRA. Conclusion practical differs significantly from clinical guidelines. Due inadequate pharmacotherapy, insufficient noncompliance investigations, 1-year therapy does lead pronounced improvement patients' class.

Language: Английский

---

Chronic and acute decompensated heart failure: topical issues

Complex Issues of Cardiovascular Diseases, Journal Year: 2022, Volume and Issue: 11(2), P. 184 - 195

Published: June 26, 2022

Highlights. The article is a review of current literary data on the problem acute decompensated heart failure. highlights basic principles diagnosis and treatment, as well problems their implementation into clinical practice. Abstract Acute failure (ADHF) life-threatening condition that requires an emergency hospitalization for intensive treatment. Moreover, it event worsens patient's further prognosis. Frequent rehospitalizations decompensation reduce life expectancy quality, are also significant economic in practical health care. increasing number patients with leads to growing seeking medical help More than half re-hospitalized within year same reason. predicted increase prevalence CHF worldwide makes management such global social problem. Patients delay, low compliance insufficient ambulatory monitoring factors need be influenced order improve epidemiology ADHF, diagnosis, treatment outpatient observation compliance, prospects modern methods remote possibilities new drugs discussed article.

Language: Английский

---

Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries)

Rational Pharmacotherapy in Cardiology, Journal Year: 2020, Volume and Issue: 16(6), P. 888 - 898

Published: Dec. 30, 2020

Aim . To study comorbidity, drug therapy and outcomes in patients with atrial fibrillation (AF) included the outpatient hospital RECVASA registries. Material methods Patients AF (n=3169; age 70.9±10.7 years; 43.1% of men) whom therapy, short-term longterm (follow-up period from 2 to 6 years) were registers (Moscow, Kursk, Tula), as well (Ryazan) AF-Yaroslavl. Results Outpatient registries (n=934), compared (n=2235), had a higher average (73.4±10.9 vs 69.9±10.5; p<0.05), proportion women ( 66.2% 53.0%; p<0.0001) combination 3-4 cardiovascular diseases (CVD), including (98.0% 81.7%, p<0.0001), also chronic noncardiac (81.5% 63.5%, risk thromboembolic complications (CHA DS -VASc 4.65±1.58 4.15±1.71; p<0.05) hemorrhagic (HAS-BLED 1.69±0.75 1.41±0.77; lower frequency prescribing appropriate pharmacotherapy for CVD (55.6% 74.6%, p<0.0001). During observation period, 633 (20.0%) died, 61.8% cases - causes. The mortality rate one year Moscow was 3.7%, Yaroslavl 9.7%, Ryazan 10.7%, Kursk 12.5% (on four 10.3%). A death (1.5-2.7 times) significantly associated age, male sex, persistent AF, history myocardial infarction (MI) acute cerebrovascular accident (ACVE), diabetes mellitus, obstructive disease lungs (COPD), heart rate>80 bpm, systolic blood pressure <110 mm Hg, decreased hemoglobin level. (1.2-2.4 prescription anticoagulants, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), betablockers, statins. number stroke MI was, respectively, 5.1 9.4 times less than deaths all during follow-up female sex (risk ratio [RR]=1.61), permanent (RR=1.85), (RR=1.68) ACVA (RR=2.69), HR>80 bpm (RR=1.50). Anticoagulant (if adjusted age: RR=0.54; p=0.04), contrast men (RR=1.11; p=0.79). Conclusion majority 5 regions Russia three or more (73.9%), non-cardiac (68.8%). proper insufficient (68.6%), especially at stage (55.6%). Over (2-6 years), per 10.3%, but same time it differed (from 3.7% 9.7-12.5% Yaroslavl, Kursk). Cardiovascular causes occurred 62%. MI, COPD, However, by 1.2-2.4 ACE inhibitors / ARBs, beta-blockers highest presence this event (2.7 2.6 times, respectively). reduced women.

Language: Английский

---